"3 large-cap pharma stocks to watch as recovery takes hold 👀
$LLY, $JNJ and $BAYRY stand out as the industry shows strong recovery, driven by innovation, positive regulatory updates and a major wave of M&A activity.
📈 LLY: Strong cardiometabolic momentum
💊 JNJ: Diversified portfolio + pipeline
🚀 BAYRY: Key drug growth + new launches
See why these 3 pharma stocks are worth watching 👉
Latest LLY news here 👉
" https://www.zacks.com/stock/quote/LLY?q=lly&art_rec=quote-stock_overview-search_filter-zcom-LLY&cid=sm-stocktwits-0-quote_overview-oc-39254&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_39254
$FRGT - let's not forget other big clientel names like $BAYRY $WHR and Kawasaki Motors.
‼️Do your DD‼️
The current marketcap is a joke.
Ride the wave 🌊💲
🎯 Easy Double-Digit run
Truist y'day⬆️ $ABCL's PT to $30,⬆️risk adj'd peak sales estimates to $1.1B, reiterated Buy and said -- ABCL635 exceeds our expectations in VMS Ph2, we see best-in-class potential
$BAYRY $ALPMY LLY VERU VTGN
Truist added—ABCL reported Ph2 4-week VMS data that exceeded our expectations.
While we await 12 week data to get a more complete profile, we believe that 4-week results position ABCL635 as clearly differentiated vs. the approved small molecules given its risk-benefit profile and the potentially once monthly injection (vs. daily oral).
We are updating our model to reflect increased confidence in the program. We now estimate peak risk-adjusted sales of $1.1B, up from $641M previously, and raise our price target to $30 per share from $12 per share previously.
$VKTX I'd be thrilled with an all share by strong player that needs metabolic, like a $GSK or $JNJ or even $BAYRY. I love how Glaxo has rebuilt Oncology and HIV, would be very cool to bring in Viking. Let's not get too excited until summer over. Summer is about rest and doldrums. People never make good decisions when too hot and miserable. September, Q4 much better time.
$BAYRY Earnings data:
"Bayer Q2 2026 Earnings
- Core EPS EU 0.95 (est EU 0.75)
- Adj EBITDA EU 2.14B (est EU 1.93B)
- Sales EU 10.87B (est EU 10.67B)
- Still Sees FY Rev. EU 45B To EU 47B (est EU 45.63B)
- Still Sees FY Neg FCF EU 1.5B To EU 2.5B
- Still Sees FY Adj. EBITDA EU 9.6B To EU 10.1B (est EU 9.61B)
- Confirms Currency-Adjusted Outlook"
Screenshot from Top Tier Newswire.
$BAYRY / $BAYERCROP.NSE investors there’s no hidden secret here. Just one thing you really need to know.
Here’s how to handle your losses. More importantly, how to either recover them or risk losing even more: https://11th.com/cases/bayer-investor-settlement
Are there any #pharma #stocks you expect a #potential #52weekhigh and or potential #tradinghalt next week? $COR $JNJ $BAYRY Good luck #potential #blockbuster #otlk 7/29/26 $OTLK #pdufa #wednesday #aging #eyes #wet #agerelated #maculardegeneration #bevacizumab
